In addition, the early iteration of Apple's device was table-top with the goal of development now to create a prototype that would still be about the size of an iPhone that could be strapped to a person's bicep, the firm points out. Opco assumes a device like this would be more consumer-like with potential use also in pre-diabetes. The firm also sees no impact from the article on continuous glucose monitoring pump partners Insulet ( PODD ) and Tandem Diabetes ( TNDM ). The analyst keeps an Outperform rating on DexCom.